SCHEMBL17276396

SCHEMBL17276396

COC(=O)c1ccc2c(c1)NC(=O)CCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
ALDH1A1 P00352 2/20 0.56
CRBN Q96SW2 2/20 0.54
ALOX15 P16050 3/20 0.48
HSD17B10 Q99714 3/20 0.48
HTT P42858 3/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 2/20 0.48
MAPK1 P28482 2/20 0.48
MEN1 O00255 1/20 0.48
FGB P02675 1/20 0.48
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
KMT2A Q03164 1/20 0.48
SMYD3 Q9H7B4 1/20 0.46
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29754229 0.91 CRBN (0.64) LMNAALDH1A1CRBNALOX15HSD17B10
SCHEMBL2497788 0.91 CRBN (0.64) LMNAALDH1A1CRBNALOX15HSD17B10
SCHEMBL7525379 0.89 CRBN (0.64) LMNAALDH1A1CRBNALOX15HSD17B10
SCHEMBL29374811 0.84 CRBN (0.59) LMNAALDH1A1CRBNHTTHPGD
SCHEMBL1359221 0.84 CRBN (0.59) LMNAALDH1A1CRBNHTTHPGD
SCHEMBL15810408 0.84 MAPT (0.51) ALDH1A1CRBNALOX15MAPTMEN1
Acetic Acid SCHEMBL30195764 0.80 CRBN (0.56) LMNAALDH1A1CRBNHTTHPGD
SCHEMBL17957924 0.80 ALDH1A1 (0.56) LMNAALDH1A1CRBNALOX15HSD17B10
SCHEMBL30955089 0.79 MAPT (0.51) LMNAALDH1A1CRBNALOX15HSD17B10
SCHEMBL6646602 0.79 CRBN (0.76) LMNAALDH1A1CRBNALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3145915-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC (US) 2025-03-19 EP disclosed
US-10000454-B2 Antidiabetic tricyclic compounds MERCK SHARP & DOHME (US) 2018-06-19 US disclosed
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-03-23 US disclosed
WO-2015176267-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000454-B2 Antidiabetic tricyclic compounds GPR119, GPR65, GPR52 LMNA 4285/4885ALDH1A1 3081/4885CRBN 4471/4885
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS GPR119, GPR65, GPR52 LMNA 4285/4885ALDH1A1 3081/4885CRBN 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.